What is DF/HCC?
Dana-Farber/Harvard Cancer Center (DF/HCC) is an NCI-designated comprehensive cancer center that unites the cancer research efforts of five Boston academic medical institutions—Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital—and two Harvard Schools—the Harvard Medical School and the Harvard T.H. Chan School of Public Health.
Am I a part of it?
If you are working on oncology research at one of the member institutions listed above, then you are a part of DF/HCC.
What does that mean for my research?
Please review the DF/HCC Protocol Review Requirements to determine whether your research must be submitted to DF/HCC. Applicable research projects are subject to DF/HCC policies and must comply with DF/HCC requirements, including the following:
- All studies conducted under DF/HCC must be submitted for centralized review and reporting. (This applies to all studies, whether reviewed by the DFCI IRB or an external single IRB)
- Anyone working on DF/HCC research must comply with specific training requirements
- View the DF/HCC Education and Training page for additional guidance on completing required training
Note - There may be additional institution-specific requirements and processes that also apply. Contact your institutional clinical trials office for guidance.